Combining TCR Therapies with Immune Checkpoint Inhibitors: The concurrent use of TCR-based therapies with checkpoint inhibitors (e.g., anti-PD-1/PD-L1) can help overcome immunosuppressive signals and reinvigorate exhausted T cells, boosting anti-tumor responses. This evidence concerns the gene CD274 and neoplasm.